Research Article
Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis
Table 1
Baseline characteristics.
| | Author | Country | Population | n | Age (SD) | Males
% | Intervention | Control group | Follow up (m) | Industry funding | Gout | HTN | CAD | HF | T2DM |
| | White [10] | US | Gout + previous CV events | 6190 | 65 IQR (58-71) | 84 | FBX 40 mg up to 80 mg | Allopurinol | 32 | Yes | 100 | 92 | 76 | - | 20 |
| | Dalbeth [21] | US | Gout | 314 | 51 (+/-12) | 92 | FBX 40 mg/ 60 mg/ 80 mg | Placebo | 24 | Yes | 100 | - | - | - | - |
| | Gunawardha [22] | US | HTN | 121 | 54 (+/-10.6) | 81 | FBX 80 mg | Placebo | 1.5 | Yes | - | 100 | - | - | - |
| | Sezai [23] | Japan | CVD | 55 | 68 (+/-9) | 83 | FBX 60 mg | Topiroxostat | 12 | Yes | - | 82 | 36 | - | 35 |
| | Ohta [24] | Japan | HTN | 20 | 64 (+/-12) | 90 | FBX 40 mg | Benzbromarone | 9 | No | - | 100 | - | - | - |
| | Beddhu [25] | US | CKD T2DM | 80 | 68 (+/-10) | 65 | FBX 80 mg | Placebo | 5.5 | Yes | - | 77 | 18 | 10 | 100 |
| | K-H [26] | China | Gout | 109 | 45 (+/-11.5) | 97 | FBX 80 mg | Allopurinol | 2.7 | Yes | 100 | - | - | - | - |
| | Sircar [27] | India | CKD | 108 | 57 (+/12.6) | 70 | FBX 40 mg | Placebo | 6 | Yes | - | 98 | 38 | - | 38 |
| | Tani [28] | Japan | HTN | 60 | 67 (+/-12) | 88 | FBX 20 mg | Placebo | 6 | No | - | 100 | 32 | - | 32 |
| | Tanaka [29] | Japan | CKD | 45 | 68 (+/-8.2) | 88 | FBX 40 mg | Allopurinol | 2.7 | No | - | 43 | - | - | - |
| | Tsuruta [30] | Japan | ESRD | 53 | 68 (+/-12.55) | 64 | FBX 10 mg | Placebo | 1 | No | - | 79 | 27 | - | 42 |
| | Xu [31] | China | Gout | 504 | 47 (+/-11.5) | 95 | FBX 40 mg/ 80 mg | Allopurinol | 5.5 | Yes | 100 | 16 | - | - | 5 |
| | Huang [32] | China | Gout | 512 | 47 (+/-11.2) | 98 | FBX 40 mg/ 80 mg | Allopurinol | 6.4 | Yes | 100 | 28 | - | - | - |
| | Sezai [33] | Japan | Cardiac surgery | 141 | 67 (+/-10.3) | 82 | FBX 60 mg | Allopurinol | 6 | No | - | 81 | 40 | - | 36 |
| | Katamani [34] | Japan | Hyperuricemia | 40 | 54 (+/-10.4) | 100 | FBX 40 mg/ 60 mg | Allopurinol | 3.6 | Yes | 76 | 42 | - | - | 5 |
| | Katamani [35] | Japan | Hyperuricemia | 202 | 53 (+/-12.7) | 97 | FBX 20 mg/ 40 mg/ 60 mg/ 80 mg | Placebo | 3.6 | Yes | 59 | 49 | - | - | 11 |
| | Katamani [36] | Japan | Hyperuricemia | 102 | 48 (+/-13.6) | 100 | FBX 20 mg/ 40 mg | Placebo | 1.8 | Yes | 49 | 35 | - | - | 11 |
| | Katamani [37] | Japan | Hyperuricemia | 244 | 52 (+/-13.5) | 98 | FBX 40 mg | Allopurinol | 1.8 | Yes | 47 | 33 | - | - | 10 |
| | Becker [38] | US | Gout | 2269 | 52 (+/-11.7) | 94 | FBX 40 mg/ 80 mg | Allopurinol | 6 | Yes | 100 | 53 | - | - | 14 |
| | Becker [39] | US | Gout | 1086 | 51 (+/-11.6) | 96 | FBX 80 mg/ 120 mg | Allopurinol | 40 | Yes | 100 | 45 | - | 1 | 7 |
| | Schumacher [40] | US | Gout | 1072 | 52 (+/-12.2) | 94 | FBX 80 mg/ 120 mg/ 240 mg | Allopurinol and placebo | 6.4 | Yes | 100 | 47 | - | - | - |
| | Becker [41] | US | Gout | 762 | 52 (+/-12.1) | 96 | FBX 80 mg/ 120 mg | Allopurinol | 12 | Yes | 100 | 44 | 10 | - | 7 |
| | Becker [42] | US | Gout | 153 | 54 (+/-12.6) | 89 | FBX 40 mg/ 80 mg/ 120 mg | Placebo | 1 | Yes | 100 | 49 | 60 | - | 13 |
| | Nakagomi [43] | Japan | HF+Hyperuricemia | 61 | 70.5 (+/-9) | 70 | FBX 40 mg | Allopurinol | 12 | No | - | 93 | 72 | 100 | 34 |
| | Saag [44] | US | Gout+CKD | 96 | 65.7 (+/-10) | 80 | FBX up to 80 mg | Placebo | 12 | Yes | 100 | 95 | - | - | 44 |
|
|
n: number of participants. HTN: hypertension. CAD: coronary artery disease. HF: heart failure. T2DM: type 2 diabetes mellitus. CV events: cardiovascular events. CKD: chronic kidney disease. ESRD: end-stage renal disease. SD: standard deviation. IQR: interquartile range. FBX: febuxostat.
|
